Due to the poor prognosis of high-risk (HR) neuroblastoma (NBL), scant data exist on late effects after treatment. Recently, protocols utilizing intense multimodal treatment have resulted in improved long-term survival. The objective of this study was to determine the prevalence of late effects in survivors of HR NBL. A retrospective review of clinical data for serial patients completing treatment between September 1994 and October 2007 and surviving for at least 1 year was performed. Therapy included aggressive chemotherapy, surgery, radiation and single or tandem SCT. Oncology follow-up was standard; clinical criteria were utilized for referrals to endocrinology and other services. Fifty-one eligible patients were identified. Median follow-up was 6.1 years (range 1.0-15.2). Height was significantly impacted (DZ-score À 1.91 in those treated with TBI and À 0.77 in those without). Pre-diabetes or diabetes, hypothyroidism and ovarian insufficiency were observed in 50, 59 and 75% of at-risk survivors, respectively. Hearing loss and dental issues were common. Nine patients had relapse of NBL; seven died of progressive disease. As there is a high prevalence of late effects in long-term survivors of HR NBL, close monitoring and further studies after treatment are indicated, and in particular after more modern, non-TBI regimens.
INTRODUCTION
Neuroblastoma (NBL) is the most common extracranial solid malignancy in pediatric patients and predominantly affects children o5 years of age. 1 Treatment is based on the risk stratification using age, stage, MYCN oncogene status and pathologic classification. Before the 1990s, high-risk (HR) patients had long-term survival of o15%.
2 Strategies employing aggressive multimodal treatment have improved outcome with reported event-free survivals at 3 years after treatment of 40-60%. 3, 4 Therapies used include surgery, intensive multiagent chemotherapy and local radiation. High-dose chemotherapy with autologous SCT has been shown to improve survival. 5 From 1994 to 2007, the majority of HR NBL patients at DFCI (Dana-Farber Cancer Institute)/BCH (Boston Children's Hospital) participated in a series of clinical trials (or were treated according to those trials) utilizing multiple cycles of 'induction' chemotherapy, aggressive surgical resection of abdominal, pelvic or thoracic primary tumors, local radiation and consolidation therapy with peripheral autologous SCT. Most patients received 'tandem' transplantation; conditioning for the first utilized chemotherapy only, and the second with melphalan and 12 Gy TBI. This approach resulted in an overall survival of 60% at 5 years and 53% at 7 years. 4 Given the aggressive treatment approach outlined above and the young age at treatment, almost all survivors are expected to have late effects related to their treatment. 6, 7 However, only limited data are available about the nature and incidence of sequelae in similarly aggressively treated long-term survivors of HR NBL. 7, 8 To further elucidate endocrine and other outcomes, we performed a comprehensive retrospective evaluation of our cohort who had been serially treated and followed.
SUBJECTS AND METHODS
Medical records were reviewed for all patients treated at initial presentation of HR NBL at DFCI/BCH between September 1994 and October 2007 and surviving at least 1 year after completion of SCT. In all, 110 patients were identified. Patients were excluded if SCT was not at DFCI/BCH (n ¼ 3), if relapsed within 1 year of SCT (n ¼ 27), or were lost to follow-up/followed at another institution after SCT (n ¼ 29). Fifty-one patients are in the cohort reviewed. The number of patients analyzed for each condition was o51 because of missing data. Data collection was stopped at time of relapse. Oncology, endocrinology, psychology, echocardiography (standard screen every other year), audiometry (standard screen annually) and dental records were reviewed for documentation of the presence or absence of specific outcomes. Anthropometric data and the presence of late effects were determined at the time of each patient's last visit to DFCI or BCH. Height and weight Z-scores were determined according to the National Center for Health Statistics. 9 Change in height or weight Z-score was only calculated if height or weight was available before treatment. Growth hormone (GH) status was assessed by insulin-like growth factor-1 (IGF-1) and GH levels after two stimulation tests (Nichols Advantage or Immulite for both IGF-1 and GH, with a high degree of correlation between assays). Hypothyroidism (standard screen yearly) was diagnosed by persistent elevation of thyrotropin (TSH). Ovarian failure was diagnosed by elevation of gonadotropin levels and a low level of estradiol in girls who were 413 years of age. Glucose intolerance was assessed by HbA1c (Roche Diagnostics Corporation, Indianapolis, IN, USA). The presence of cataracts, renal dysfunction, and pulmonary dysfunction (known side effects) was not evaluated. Variables of sex were analyzed when numbers permitted (hearing, hypothyroidism and dental issues). Variables of age were not analyzed, as the majority were young at diagnosis. The Spearman's rank correlation coefficient was used to assess the correlation between change in height Z-score and length of follow-up; and change in height Z-score vs change in weight Z-score. The Fisher's exact test was used to assess the relative prevalence in males vs females of hearing loss and hearing aids, hypothyroidism and dental issues; of prediabetes in patients treated with or without abdominal radiation; and of hypothyroidism in patients treated with or without TBI.
RESULTS
The median age at diagnosis of HR NBL was 2.7 years (range 0.2-15.5). The median time to most recent follow-up was 6.1 years (range 1.0-15.2). Demographic and clinical data are shown in Table 1 .
Forty-six patients were treated on or as per local protocol 94-131 (see Figure 1 for schema). Of these, 5 received a single SCT with chemotherapy conditioning only and 41 underwent tandem transplantation. An additional three patients were treated on COG ANBL00P1 with SCT conditioning with thiotepa and CY, followed by a second SCT with carboplatin, etoposide and melphalan conditioning. The remaining two patients were treated on protocol COG A3973 with a single SCT conditioning with carboplatin, etoposide and melphalan. In all, 41/51 (80%) received TBI (Table 1) . Ninety-six percent received 13-cis-retinoic acid following SCT. No patients received therapeutic MIBG (meta-iodobenzylguanidine) or anti-GD2 Ab.
Patients had a decrease in linear growth. Mean change in height Z-scores from pre-treatment to most recent visit was À 1.91 in survivors who had received TBI and À 0.77 in those who had not (P ¼ 0.003). Change in height Z-score was directly related to length of follow-up (r ¼ À 0.509, Po0.0001) and to decrease in weight Z-score (r ¼ 0.452, Po0.001) (Figure 2 ). Mean BMI Z-score was À 0.09 (1.24).
Seven of the fifty-one patients (14%), all of whom received TBI, were given GH therapy 0.18-0.3 mg/kg/week divided daily with goal IGF-1 in upper normal range. Diagnostic evaluations for GH deficiency (GHD) in these patients showed abnormal GH stimulation testing and low IGF-1 (n ¼ 1), normal GH stimulation testing and normal IGF-1 (n ¼ 4), abnormal GH stimulation testing and normal IGF-1 (n ¼ 1) and data unavailable (n ¼ 1) (Table 2a ). The five patients with normal IGF-1 levels were initially felt to have low IGF-1 levels based on older reference ranges and, therefore, GH neurosecretory dysfunction. Median age at start of GH treatment was 9.1 years (range 5.1-11.1 years). Two patients (patient 1, male, (Table 2b) , though the impact of GH therapy on his adult height cannot be predicted. There were four patients still growing who had been treated for 41 year but o2.1 years with average Dheight Z-score of þ 0.4 at 1 year (Table 2b ; Figure 3 ), similar to the first year response in those at short adult height. Several other endocrine late effects were noted. HbA1c levels were measured in 24 patients, all of whom had received TBI. Nearly half (11/24) were in the pre-diabetes range of 5.7-6.4%, 10 and the overall mean HbA1c was 5.7±0.3 (normal range 4.0-6.0) (Figure 4) . Those who received abdominal radiation did not have a higher incidence of pre-diabetes. BMI did not correlate with HbA1c, and BMI in those with HbA1c X5.7% was not significantly different from those with o5.7% (data not shown). One additional patient had developed clinically evident type 2 diabetes mellitus (DM), presenting with acanthosis nigricans; she had not received abdominal radiation.
Compensated hypothyroidism (elevated TSH/normal free thyroxine) was noted in over half of the patients (29/49, 59%), and replacement therapy was initiated. The prevalence of hypothyroidism increased over time: 45% of patients who were 1-5 years from completion of treatment and 56% who were 5-10 years after treatment. In those patients 410 years after treatment, the prevalence was 85%. Development of hypothyroidism was strongly associated with a history of TBI with an odds ratio of 22.09 (95% confidence interval 2.49-195.75, P ¼ 0.001). There was no sex-related difference.
Premature ovarian insufficiency (POI) was seen in females of adolescent age, age 13 years or greater (9/12, 75%) ( Table 3 ) and was treated with hormonal replacement. Of those with POI, 7/9 had spontaneous but incomplete puberty, 1 was post-menarchal at diagnosis with NBL but had subsequent POI, and 1 showed no pubertal development at age 13 years. All patients with POI had received TBI, while two of the three with apparent normal function to date did not. Only about half (5/9) with POI had received abdominal radiation. All males of adolescent age progressed through puberty, but had small testicular size consistent with Sertoli cell damage and likely infertility.
There were also several non-endocrine late effects. The majority of patients had sensorineural hearing loss (37/51, 73%). Interestingly, severe hearing loss, as evidenced by use of hearing aids, was more common in males (15/29, 52%) than in females (5/22, 23%) with an odds ratio of 3.64 (95% confidence interval 1.06-12.52, P ¼ 0.046). Dental disease was reported in the majority of patients (23/45, 51%), predominantly dental caries (13/45, 29%) but also abnormal development of the teeth (9/45, 20%). There was no sex-related difference. Special education needs (individualized Patient was diagnosed at a separate institution, and data are not available.
Late effects in high-risk neuroblastoma survivors LE Cohen et al education plans or 501b plans), cardiac dysfunction as assessed by echocardiogram and scoliosis were also observed (Table 3) . In all, 2 of 49 (4%) patients developed second neoplasms: synovial cell sarcoma of the neck (treated with surgical resection and local radiation) and hepatoblastoma (treated with surgical resection and chemotherapy) developed 7.5 and 2.4 years, respectively, from completion of NBL therapy. Both had received TBI; the latter had received local radiation but at a distant site (left iliac crest). Both are still alive after treatment. In all, 9 of 51 (18%) patients had NBL relapse, and 7 of these have died (7/51 (14%) of original cohort; 7/9 (78%) of relapse cohort).
DISCUSSION
While treating HR NBL is still a challenge, patients in the modern era have better long-term survival compared with historical controls. This improvement in outcome is associated with the development of significant sequelae affecting many different organ systems. These patients are often very young at diagnosis, and current approach involves aggressive multimodal treatment including autologous SCT. For many of our patients, TBI was also a part of the therapeutic plan. Height was significantly impacted, and hypothyroidism, ovarian failure, hearing loss and dental issues were quite common. Other effects included cardiac dysfunction, scoliosis and special education needs. The strength of this study is that it evaluated a large group of patients treated in a relatively uniform manner. Additionally, some patients had very long-term follow-up with 14 patients being at least 10 years from completion of treatment (range 10.1-15.2 years). This represents one of the largest cohorts of young patients receiving TBI in the setting of autologous SCT. In addition, because some patients did not receive TBI, we could explore the additive effect of TBI on growth when given in the setting of prior chemotherapy, local radiation and chronic illness.
The majority of these patients had growth failure with a very strong correlation between decrease in height Z-score and time from diagnosis. Patients who did not receive TBI were significantly taller than those who had received TBI, similar to the findings of Hovi et al. 11 TBI is the one treatment modality that might place these patients at risk for GH insufficiency. However, they did not test as GH deficient on stimulation testing or appear to have GH neurosecretory dysfunction; and while short-term response to GH treatment was good, long-term outcome was not. In addition, height Z-score decrease was directly related to weight Z-score decrease. As weight Z-score is often maintained with GHD, it suggests that other mechanisms besides GHD may be affecting their height. Lack of true GHD is consistent with the findings of Trahair et al. 12 who noted only 1/13 HR NBL patients with growth failure who had received TBI for SCT had GHD. On the other hand, Perwein et al. 13 diagnosed GHD in 6 of 16 HR NBL survivors (37.5%), 13 of whom had received transplant but only 1 of whom had received TBI. However, they did not state their diagnostic criteria, and diagnosis was made at a median time of only 11.5 months after therapy (range 0-134). The literature supports other factors besides GHD compromising growth in this patient population. Willi et al.
14 suggested that the intensive chemotherapy for NBL may be a significant risk factor for poor growth. Even when controlled for age, NBL patients after SCT had less response to GH therapy than hematologic malignancies after SCT. 15 Almost all our patients received 13-cisretinoic acid, which is associated with premature epiphyseal closure. 16 We did not have adequate bone age data to assess this. Scoliosis, which can contribute to short stature, was only noted in 4% of our patients but may not have been adequately assessed, as Laverdierre et al. 6 reported a rate of 14%. TBI and abdominal and pelvic radiation might have compromised spine growth, but we were unable to adequately assess this due to lack of body proportion measurements.
HbA1c levels tended to be on the higher end of normal, with one patient developing type 2 DM and half of the patients having evidence of pre-diabetes. Impaired glucose tolerance and insulin resistance have been reported in adult survivors of ALL and AML after SCT with TBI, 17 as well as in survivors of childhood cancers treated with SCT. 18, 19 Additionally, increased prevalence of DM has been reported in cancer survivors who were treated with SCT. [20] [21] [22] Lorini et al. 20 found that insulin resistance develops in those treated with radiation, but mostly after TBI, while Hoffmeister et al. 21 did not find TBI as a significant risk factor. Meacham et al. 22 noted that TBI, abdominal radiation, use of alkylating agents, and a younger age at diagnosis were risk factors for DM in childhood cancer survivors. They also found that survivors of NBL treated with abdominal radiation had a greater risk of developing DM than sibling controls. We did not find TAI to be a risk factor, but our numbers were small. It remains unclear exactly which is causing the alterations in glucose metabolism in our patients.
Like other studies of patients with NBL, 8, 13, 23 the occurrence of hypothyroidism was much higher than that seen after SCT in children for other malignancies. [24] [25] [26] The higher rate may be due to treatment at younger age as supported by data from Ishiguro et al. 27 and/or due to damage from diagnostic 131 I-MIBG in spite of potassium iodide prophylaxis. 23 While MIBG scans can cause transient hypothyroidism and could have inflated the numbers depending on when thyroid function was checked, permanent thyroid dysfunction is likely a real finding as the rates in the group 10-15 years from treatment were almost double that of the other groups.
Of the 12 female patients who had reached adolescence, a high proportion entered puberty spontaneously, but the majority did not complete puberty on their own. POI appeared related to TBI rather than abdominal radiation. Other published reports have found that 30-50% of pre-pubertal girls enter puberty spontaneously after SCT. 28, 29 Our higher rate may be due to the younger age of our cohort at time of cancer treatment. POI remains a risk even when having normal pubertal transit, and thus, girls must have long-term counseling and endocrinology follow-up.
Three-quarters of our patients had sensorineural hearing loss and half of our patients had dental issues. In the only comparably treated but much smaller cohort evaluated to date, Hobbie et al. 8 found that hearing loss and dental abnormalities were their most common sequelae, impacting 490% of their survivors. Carboplatin is a common component of the SCT regimen for NBL and is known to be ototoxic. Ototoxicity has been reported in other heterogeneous cohorts of patients with various stages of NBL, 7 and patients with NBL receiving auto-SCT seem to have a higher prevalence. 30 Patients who receive SCT are more likely to have had previous platinum therapy, in addition to that in the conditioning regimen. In addition, they may have had greater exposure to other ototoxins such as aminoglycoside antibiotics, diuretics and noise exposure, 30 which were not evaluated in our study. We found a sex-related difference in hearing loss with males affected more than females. This may reflect a normal pre-disposition, as the prevalence of any hearing loss and of high frequency hearing loss is greater in males than in females in the general adolescent population. 31 Hearing loss may impact speech development, 30 and some of our patients were noted to require speech therapy. Of dental Late effects in high-risk neuroblastoma survivors LE Cohen et al findings, our most common was caries. Radiation increases the caries susceptibility of dentin. 32 Poor root or tooth development may be due to treatment with alkylating agents with or without radiation at a young age. 33, 34 As in other studies of HR NBL patients, cardiac dysfunction and need for special education, while present, were less common. 35 TBI, mediastinal radiation and/or anthracycline exposure are all possible explanations for cardiotoxicity but were not explored.
Other limitations of this study include its retrospective nature, reliance on clinical reports that were often incomplete, and loss of patients to follow-up if they returned to their home institution. In addition, the small numbers restricted our ability to assess additional risk factors.
In conclusion, as the outcome for children with HR NBL improves, it has become clear that the survivors are at risk of a multiplicity of late effects. Many of these may be related to TBI exposure; while TBI is no longer used in NBL conditioning regimens, it will be replaced by BU in future studies. Data from hematologic malignancies suggest that BU causes similar longterm sequelae. Some sequelae appear soon after diagnosis, but many present or worsen as length of time from SCT lengthens. Thus, regular surveillance by specialists for the development of these issues is critical. Prospective studies of uniform cohorts with consistent evaluation are necessary to better define absolute risks over time.
Additional data post-analysis As of 6/2012, one patient developed metastatic papillary thyroid cancer. Two additional patients died of progressive neuroblastoma; one had relapse after the initial data collection. Of the patients treated with GH, patient 3 is at adult height at age 16.1 years with a current height Z-score of À 2.91.
